SCHEMBL30135246

SCHEMBL30135246

FC(F)(F)c1cc2c(Br)ccnc2[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 3/20 0.45
▸ CHUK O15111 3/20 0.45
▸ PRKCI P41743 1/20 0.44
▸ CSNK1D P48730 1/20 0.42
▸ MAPK14 Q16539 1/20 0.42
▸ CIT O14578 1/20 0.40
▸ DAO P14920 1/20 0.39
▸ KDM4E B2RXH2 4/20 0.33
▸ CCNB2 O95067 1/20 0.33
▸ CDK1 P06493 1/20 0.33
▸ CCNB1 P14635 1/20 0.33
▸ GSK3A P49840 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ CCNB3 Q8WWL7 1/20 0.33
▸ AXL P30530 1/20 0.33
▸ PTK6 Q13882 1/20 0.32
▸ RAD51 Q06609 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.31
▸ HPGD P15428 2/20 0.31
▸ KIF11 P52732 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1431235 0.83 IKBKB (0.45) IKBKBCHUKPRKCICSNK1DMAPK14
SCHEMBL2986312 0.79 IKBKB (0.45) IKBKBCHUKCSNK1DMAPK14CIT
SCHEMBL2984796 0.79 IKBKB (0.45) IKBKBCHUKPRKCICSNK1DMAPK14
SCHEMBL30509532 0.79 IKBKB (0.45) IKBKBCHUKPRKCICSNK1DMAPK14
SCHEMBL13014174 0.79 IKBKB (0.45) IKBKBCHUKCSNK1DMAPK14CIT
SCHEMBL15646519 0.76 IKBKB (0.44) IKBKBCHUKCSNK1DMAPK14CIT
SCHEMBL15646394 0.76 CDC7 (0.44) IKBKBCHUKCSNK1DMAPK14CIT
SCHEMBL15645163 0.73 CHUK (0.44) IKBKBCHUKCSNK1DMAPK14CIT
SCHEMBL24493222 0.73 PRKCI (0.48) PRKCIDAOCCNB2CDK1CCNB1
SCHEMBL4319429 0.73 PRKCI (0.48) PRKCIDAOKDM4ECCNB2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243196-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION 2025-07-31 — — US disclosed
WO-2022216717-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION (US) 2022-10-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243196-A1 CITRON KINASE INHIBITORS CHEK2, CILK1, DCK IKBKB 596/4885CHUK 324/4885PRKCI 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback